Harbor Investment Advisory LLC Has $30,000 Position in Palantir Technologies Inc. (NYSE:PLTR)

Harbor Investment Advisory LLC cut its stake in shares of Palantir Technologies Inc. (NYSE:PLTR – Get Rating) by 80.6% during the 2nd quarter, Holdings Channel reports. The fund owned 3,300 shares of the company’s stock after selling 13,750 shares during the period. Harbor Investment Advisory LLC’s holdings in Palantir Technologies were worth $30,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. IndexIQ Advisors LLC bought a new position in shares of Palantir Technologies during the 1st quarter worth $27,000. Endurance Wealth Management Inc. bought a new position in Palantir Technologies during the first quarter worth about $27,000. Herold Advisors Inc. purchased a new position in shares of Palantir Technologies in the first quarter worth about $35,000. TCI Wealth Advisors Inc. raised its position in shares of Palantir Technologies by 58.5% in the first quarter. TCI Wealth Advisors Inc. now owns 2,820 shares of the company’s stock valued at $39,000 after purchasing an additional 1,041 shares during the period. Finally, UMB Bank NA MO lifted its stake in shares of Palantir Technologies by 58.6% during the 1st quarter. UMB Bank NA MO now owns 3,240 shares of

Duck Creek Technologies (NASDAQ:DCT) Sees Unusually-High Trading Volume

Shares of Duck Creek Technologies, Inc. (NASDAQ:DCT – Get Rating) saw strong trading volume on Monday . 21,954 shares changed hands during mid-day trading, a decline of 97% from the previous session’s volume of 823,367 shares. The stock last traded at $11.95 and had previously closed at $11.65.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. DA Davidson cut their price objective on Duck Creek Technologies to $30.00 in a research report on Monday, July 4th. Royal Bank of Canada lowered Duck Creek Technologies from an “outperform” rating to a “sector perform” rating and dropped their price target for the company from $18.00 to $14.00 in a research report on Tuesday, July 19th. JMP Securities lowered Duck Creek Technologies from an “outperform” rating to a “market perform” rating in a research report on Friday, July 1st. Raymond James dropped their price target on Duck Creek Technologies from $24.00 to $18.00 and set an “outperform” rating on the stock in a research report on Thursday, June 30th. Finally, Bank of America lowered Duck Creek Technologies from a “buy” rating to a “neutral” rating and dropped their price target for the company from $39.00

Mercer Global Advisors Inc. ADV Takes Position in Ormat Technologies, Inc. (NYSE:ORA)

Mercer Global Advisors Inc. ADV acquired a new stake in Ormat Technologies, Inc. (NYSE:ORA – Get Rating) during the 1st quarter, Holdings Channel reports. The firm acquired 3,452 shares of the energy company’s stock, valued at approximately $282,000.

Several other large investors have also made changes to their positions in the business. Advisor Group Holdings Inc. lifted its position in shares of Ormat Technologies by 2.6% in the first quarter. Advisor Group Holdings Inc. now owns 5,824 shares of the energy company’s stock valued at $522,000 after acquiring an additional 147 shares in the last quarter. Signaturefd LLC lifted its position in shares of Ormat Technologies by 77.6% in the first quarter. Signaturefd LLC now owns 451 shares of the energy company’s stock valued at $37,000 after acquiring an additional 197 shares in the last quarter. Prospera Financial Services Inc purchased a new position in shares of Ormat Technologies in the first quarter valued at about $41,000. Teacher Retirement System of Texas lifted its position in shares of Ormat Technologies by 6.5% in the first quarter. Teacher Retirement System of Texas now owns 9,213 shares of the energy company’s stock valued at $754,000 after acquiring an additional 563 shares in

Qube Research & Technologies Ltd Sells 17,083 Shares of BioAtla, Inc. (NASDAQ:BCAB)

Qube Research & Technologies Ltd decreased its position in shares of BioAtla, Inc. (NASDAQ:BCAB – Get Rating) by 48.8% in the 1st quarter, Holdings Channel reports. The fund owned 17,936 shares of the company’s stock after selling 17,083 shares during the quarter. Qube Research & Technologies Ltd’s holdings in BioAtla were worth $90,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Los Angeles Capital Management LLC bought a new position in shares of BioAtla during the 1st quarter worth $333,000. Woodline Partners LP grew its stake in shares of BioAtla by 196.1% during the 4th quarter. Woodline Partners LP now owns 446,141 shares of the company’s stock worth $8,758,000 after acquiring an additional 295.446 shares during the period. Russell Investments Group Ltd. bought a new position in shares of BioAtla during the 1st quarter worth $286,000. SG Americas Securities LLC grew its stake in shares of BioAtla by 165.0% during the 1st quarter. SG Americas Securities LLC now owns 13,524 shares of the company’s stock worth $68,000 after acquiring an additional 8,421 shares during the period. Finally, Nisa Investment Advisors LLC purchased a

Axcelis Applied sciences (NASDAQ:ACLS) PT Raised to $95.00

Axcelis Applied sciences (NASDAQ:ACLS – Get Ranking) had its value goal raised by inventory analysts at B. Riley from $80.00 to $95.00 in a report issued on Friday, The Fly stories. B. Riley’s goal value factors to a possible upside of 21.51% from the inventory’s earlier shut. B. Riley additionally issued estimates for Axcelis Applied sciences’ Q3 2022 earnings at $1.13 EPS, This fall 2022 earnings at $1.01 EPS, FY2022 earnings at $4.68 EPS, Q1 2023 earnings at $1.08 EPS, Q2 2023 earnings at $1.18 EPS, Q3 2023 earnings at $1.24 EPS , This fall 2023 earnings at $1.27 EPS and FY2023 earnings at $4.77 EPS.

A variety of different analysts have additionally not too long ago commented on ACLS. StockNews.com minimize shares of Axcelis Applied sciences from a “strong-buy” score to a “purchase” score in a analysis notice on Wednesday, July twentieth. Needham & Firm LLC elevated their value goal on shares of Axcelis Applied sciences from $76.00 to $87.00 and gave the corporate a “purchase” score in a analysis notice on Friday. 5 analysts have rated the inventory with a purchase score, In line with MarketBeat.com, the corporate has a consensus score of “Purchase” and a mean goal

LHSC names presidents for its three hospitals amongst govt shakeup

London Well being Sciences Heart has appointed three new presidents and three different top-ranking executives, the most recent transfer in a significant shakeup of the hospital’s highest ranks.

Article content material

London Well being Sciences Heart has appointed three new presidents and three different top-ranking executives, the most recent transfer in a significant shakeup of the hospital’s highest ranks.

Commercial 2

Article content material

Nash Syed, LHSC’s interim vice-president of medical packages, is taking the helm of Kids’s Hospital, whereas interim chief medical officer Cathy Vandersluis will grow to be president of College Hospital.

Deborah Wiseman, the chief nursing govt on the Huron Perth Well being Care Alliance, will grow to be president of Victoria Hospital within the fall.

“Whereas we’re one staff unified round our frequent mission, College, Victoria and Kids’s hospitals every have a singular identification with particular person strengths and alternatives,” the hospital stated in a press release Tuesday.

“Every president will work

Analysis Analysts Provide Predictions for Procore Applied sciences, Inc.’s Q2 2022 Earnings (NASDAQ:PCOR)

Procore Applied sciences, Inc. (NASDAQ:PCOR – Get Ranking) – Equities researchers at Oppenheimer issued their Q2 2022 EPS estimates for Procore Applied sciences in a analysis notice issued to traders on Wednesday, July twenty seventh. Oppenheimer analyst Ok. Wong anticipates that the corporate will submit earnings of ($0.46) per share for the quarter. Oppenheimer has a “Assumes” score on the inventory. The consensus estimate for Procore Applied sciences’ present full-year earnings is ($1.81) per share. Oppenheimer additionally issued estimates for Procore Applied sciences’ Q3 2022 earnings at ($0.48) EPS, This autumn 2022 earnings at ($0.49) EPS, FY2022 earnings at ($1.85) EPS, FY2023 earnings at ($1.83) EPS and FY2024 earnings at ($1.65) EPS.

A number of different analysts have additionally just lately weighed in on PCOR. JPMorgan Chase & Co. dropped their value goal on Procore Applied sciences from $113.00 to $95.00 in a report on Thursday, June sixteenth. The Goldman Sachs Group dropped their value goal on Procore Applied sciences from $90.00 to $77.00 and set a “impartial” score for the corporate in a report on Thursday, April 14th. Jefferies Monetary Group dropped their value goal on Procore Applied sciences from $90.00 to $75.00 in a report on Monday, Might

Maxar Applied sciences Inc. (NYSE:MAXR) Receives Consensus Ranking of “Average Purchase” from Analysts

Maxar Applied sciences Inc. (NYSE:MAXR – Get Ranking) has obtained a consensus suggestion of “Average Purchase” from the fifteen brokerages which might be masking the corporate, Marketbeat experiences. One analysis analyst has rated the inventory with a promote ranking, three have issued a maintain ranking and eight have assigned a purchase ranking to the corporate. The typical 12-month value goal amongst brokerages which have issued a report on the inventory within the final 12 months is $38.93.

Various analysis analysts not too long ago weighed in on the inventory. TD Securities raised their value goal on shares of Maxar Applied sciences from $43.00 to $45.00 and gave the corporate a “purchase” ranking in a analysis notice on Thursday, Could twenty sixth. Canaccord Genuity Group raised their value goal on shares of Maxar Applied sciences to $40.00 and gave the corporate a “purchase” ranking in a analysis notice on Wednesday, Could twenty fifth. Citigroup raised shares of Maxar Applied sciences from a “maintain” ranking to a “purchase” ranking and decreased their value goal for the corporate from $42.00 to $38.00 in a analysis notice on Tuesday, Could tenth. They famous that the transfer was a valuation name. Financial institution of America

Veteran nurse shares why some are leaving affected person care

Behind the story of emergency room closures throughout the nation are the employees impacted, like “Sue,” a 25-year veteran nurse in Ontario who overtly weeps about her resolution to go away front-line medical care.

The 52-year-old, who has been independently verified to have been a nurse by CTVNews.ca however requested to guard her id, stated she liked her job caring for sufferers, having labored as an working room nurse, in surgical care wards, and in rehab and palliative care.

However since February, she has been off work on stress depart and is seeing a psychologist after struggling burnout.

Following two intense years working in the course of the peak of the COVID-19 pandemic, Sue stated each she and colleagues have confronted “bullying” by directors, who she claims pressure them into caring for too many sufferers than can be thought of protected. Others, she claims, are ordered to do obligatory time beyond regulation to fill in for employees shortages, as a consequence of sickness, exhaustion or as a result of colleagues have been quitting.

“After I take into consideration nursing now… I get the shakes,” she stated. “There was all the time a touch of ‘do not you dare name in